Company Overview and News

0
LafargeHolcim's Indonesia prize has cement shoes: Anjani Trivedi

16h theedgemarkets
(Aug 21): As the world’s largest cement maker sheds assets, billionaires and industrial conglomerates are lining up for LafargeHolcim Ltd’s US$2 billion-worth of Indonesian kilns. A domestic buyer may be the best (only?) option.
DB HLBZF HCMLY PTHIY 532538 UCLQF THYCY ULTRACEMCO HCMLF UCLQY 5233 PTHIF HDELY THYCF

0
YTL Corp's Francis Yeoh among Asian tycoons weighing bids for LafargeHolcim arm valued up to US$2b

2018-08-17 theedgemarkets
SINGAPORE (Aug 17): LafargeHolcim Ltd’s sale of its Indonesian unit has drawn interest from Asian billionaires and regional rivals including Japan’s Taiheiyo Cement Corp, people with knowledge of the matter said.
HLBZF HCMLY HCMLF 5233 HDELY THYCF THYCY

0
LafargeHolcim's (HCMLY) CEO Jan Jenisch on Q2 2018 Results - Earnings Call Transcript

2018-07-28 seekingalpha
Ladies and gentlemen, good morning or good afternoon. Welcome to the Half Year 2018 Results Conference Call. I'm Mara, the Chorus Call operator. The conference must not be recorded for publication or broadcast.
HCMLY

0
LAFARGEHOLCIM LTD ADR 2018 Q1 - Results - Earnings Call Slides

2018-07-27 seekingalpha
The following slide deck was published by LAFARGEHOLCIM LTD ADR in conjunction with their 2018 Q1 earnings call.
HCMLY HCMLF

0
Ambuja Cements posts 27% rise in second-quarter profit, beats expectations

2018-07-25 moneycontrol
India's Ambuja Cements Ltd posted a 27 percent growth in second-quarter profit on Wednesday, beating market estimates, helped by higher cement sales and lower expenses.
HCMLY 500425 HCMLF AMBUY AMBUJACEM

0
ACC Q2 profit beats expectations

2018-07-23 moneycontrol
Indian cement producer ACC Ltd posted a higher-than-expected 1.2 percent rise in second-quarter profit on Monday, helped by a fall in expenses.
HCMLY HCMLF TRI

0
LafargeHolcim's (HCMLY) CEO Jan Jenisch on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Ladies and gentlemen, good morning. Welcome to the LafargeHolcim Q1 2018 Results Conference Call. I'm Cher, the Chorus Call operator. [Operator Instructions] The conference must not be recorded for publication or broadcast.
HCMLY

0
LAFARGEHOLCIM LTD ADR 2018 Q1 - Results - Earnings Call Slides

2018-05-12 seekingalpha
The following slide deck was published by LAFARGEHOLCIM LTD ADR in conjunction with their 2018 Q1 earnings call.
HCMLY

37
Sensex loses 261 pts in 2 straight sessions after hitting 3-month high; PC Jeweller up 44%

2018-05-04 moneycontrol
Profit booking and weak Asian cues pulled the market lower for the second consecutive session today after hitting a three-month high Wednesday. ITC, Reliance Industries, Infosys and select banking and financials stocks led the market down.
BAJAJ-AUTO 500325 HCMLY 500425 533150 RELIANCE TCHQY 532977 BHRQY AMBUJACEM 532755 532215 505200 532541 AMBUY AXISBANK RIGD HDFCBANK BHARTIARTL EICHERMOT RLNIY NIITTECH YESBANK ECQRY AXB IBN 532648 YYBKY HEXAWARE 532129 TECHM AXBKY 532454 AXBA ICICIBANK GODREJPROP HCMLF HDB 532174 500180 534809 PCJEWELLER

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 50586V108